Citations (120)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Chao-Di Chang, Min-Wu Chao, Hsueh-Yun Lee, Yi-Ting Liu, Huang-Ju Tu, Ssu-Ting Lien, Tony Eight Lin, Tzu-Ying Sung, Shih-Chung Yen, Sing-Han Huang, Kai-Cheng Hsu & Shiow-Lin Pan. (2023) In silico identification and biological evaluation of a selective MAP4K4 inhibitor against pancreatic cancer. Journal of Enzyme Inhibition and Medicinal Chemistry 38:1.
Read now
Read now
Jolien M.R. Van der Meer, Paul K.J.D. de Jonge, Anniek B. van der Waart, Alexander C. Geerlings, Jurgen P. Moonen, Jolanda Brummelman, Janne de Klein, Malou C. Vermeulen, Ralph J.A. Maas, Nicolaas P.M. Schaap, Janneke S. Hoogstad-van Evert, Petronella B. Ottevanger, Joop H. Jansen, Willemijn Hobo & Harry Dolstra. (2021) CD34+ progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rgnull mice. OncoImmunology 10:1.
Read now
Read now
Zhe Chen, Yuanqiang Zheng, Yanchun Shi & Zhengrong Cui. (2018) Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles. International Journal of Nanomedicine 13, pages 319-336.
Read now
Read now
Yuhang Tian, Zhao Liu, Lei Zhang, Jia Zhang, Xue Han, Qiucheng Wang & Wen Cheng. (2018) Apatinib-loaded lipid nanobubbles combined with ultrasound-targeted nanobubble destruction for synergistic treatment of HepG2 cells in vitro. OncoTargets and Therapy 11, pages 4785-4795.
Read now
Read now
Fei Feng, Bin Wang, Xiuxuan Sun, Yumeng Zhu, Hao Tang, Gang Nan, Lijuan Wang, Bo Wu, Muren Huhe, Shuangshuang Liu, Tengyue Diao, Rong Hou, Yang Zhang & Zheng Zhang. (2017) Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma. Cancer Biology & Therapy 18:1, pages 51-62.
Read now
Read now
Srilakshmi Srinivasan, Judith A. Clements & Jyotsna Batra. (2016) Single nucleotide polymorphisms in clinics: Fantasy or reality for cancer?. Critical Reviews in Clinical Laboratory Sciences 53:1, pages 29-39.
Read now
Read now
Daniela Morales-Espinosa, Silvia García-Román, Niki Karachaliou & Rafael Rosell. (2015) Pharmacogenomics in the Treatment of Lung Cancer: an Update. Pharmacogenomics 16:15, pages 1751-1760.
Read now
Read now
Piyanuch Wonganan, Woon-Gye Chung, Saijie Zhu, Kaoru Kiguchi, John DiGiovanni & Zhengrong Cui. (2012) Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells. Cancer Biology & Therapy 13:10, pages 908-914.
Read now
Read now
Federico Innocenti. (2012) Research Highlights: Highlights from the Latest Articles in Germline Genomics in Oncology. Pharmacogenomics 13:10, pages 1113-1114.
Read now
Read now
Hye In Woo, Ka-Kyung Kim, Hangseok Choi, Seonwoo Kim, Kee-Taek Jang, Jun Ho Yi, Young Suk Park, Joon Oh Park & Soo-Youn Lee. (2012) Effect of Genetic Polymorphisms on Therapeutic Response and Clinical Outcomes in Pancreatic Cancer Patients Treated with Gemcitabine. Pharmacogenomics 13:9, pages 1023-1035.
Read now
Read now
Christopher A Koczor, Rebecca A Torres & William Lewis. (2012) The role of transporters in the toxicity of nucleoside and nucleotide analogs. Expert Opinion on Drug Metabolism & Toxicology 8:6, pages 665-676.
Read now
Read now
PaulaX. Fernández-Calotti, Dolors Colomer & Marçal Pastor-Anglada. (2011) Translocation of Nucleoside Analogs Across the Plasma Membrane in Hematologic Malignancies. Nucleosides, Nucleotides & Nucleic Acids 30:12, pages 1324-1340.
Read now
Read now
Anne J Grotenhuis, Sita H Vermeulen & Lambertus A Kiemeney. (2010) Germline Genetic Markers for Urinary Bladder Cancer Risk, Prognosis and Treatment Response. Future Oncology 6:9, pages 1433-1460.
Read now
Read now
Ekaitz Errasti-Murugarren & Marçal Pastor-Anglada. (2010) Drug Transporter Pharmacogenetics in Nucleoside-Based Therapies. Pharmacogenomics 11:6, pages 809-841.
Read now
Read now
Articles from other publishers (106)
Cristina Morán-Serradilla, Daniel Plano, Carmen Sanmartín & Arun K. Sharma. (2024) Selenization of Small Molecule Drugs: A New Player on the Board. Journal of Medicinal Chemistry 67:10, pages 7759-7787.
Crossref
Crossref
Clara Appiah, Shitian Chen, Afia Ibnat Pori, Vladimir Retyunskiy, Chimeng Tzeng & Ye Zhao. (2024) Study of alloferon, a novel immunomodulatory antimicrobial peptide (AMP), and its analogues. Frontiers in Pharmacology 15.
Crossref
Crossref
Inês Mendes & Nuno Vale. (2024) Overcoming Microbiome-Acquired Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Biomedicines 12:1, pages 227.
Crossref
Crossref
Songtao Zhou, Hao Tian, Jie Yan, Zhan Zhang, Guohao Wang, Xinying Yu, Wei Sang, Bei Li, Greta S.P. Mok, Jie Song & Yunlu Dai. (2024) IR780/Gemcitabine-conjugated metal-phenolic network enhanced photodynamic cancer therapy. Chinese Chemical Letters 35:1, pages 108312.
Crossref
Crossref
M. R. Yanova, A. P. Zhiyanov, I. D. Antipenko, S. A. Slobodov & E. V. Stepanova. (2023) Intracellular Gemcitabine Monophosphate Levels Predict Chemotherapy Efficacy in Gemcitabine-Treated Patients with Bladder Cancer. Doklady Biochemistry and Biophysics 513:1, pages 324-327.
Crossref
Crossref
M. R. Yanova, A. P. Zhiyanov, I. D. Antipenko, S. A. Slobodov & E. V. Stepanova. (2023) INTRACELLULAR GEMCITABINE MONOPHOSPHATE LEVELS PREDICT CHEMOTHERAPY EFFICACY IN GEMCITABINE-TREATED PATIENTS WITH BLADDER CANCER. Доклады Российской академии наук. Науки о жизни 513:1, pages 581-585.
Crossref
Crossref
Zhichao Tian & Weitao Yao. (2023) Chemotherapeutic drugs for soft tissue sarcomas: a review. Frontiers in Pharmacology 14.
Crossref
Crossref
Arunta Samankul, Gulsiri Senawong, Suppawit Utaiwat, Jeerati Prompipak, Khanutsanan Woranam, Chanokbhorn Phaosiri, Banchob Sripa & Thanaset Senawong. (2023) Tiliacora triandra Leaf Powder Ethanolic Extract in Combination with Cisplatin or Gemcitabine Synergistically Inhibits the Growth of Cholangiocarcinoma Cells In Vitro and in Nude Mouse Xenograft Models. Medicina 59:7, pages 1269.
Crossref
Crossref
Guettchina Telisnor, David L. DeRemer, Esther Frimpong, Edward Agyare, John Allen, Luisel Ricks-Santi, Bo Han, Thomas George & Sherise C. Rogers. (2023) Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans. Journal of the National Medical Association 115:2, pages 164-174.
Crossref
Crossref
Shengyong Geng, Xianbin Zhang, Tingting Luo, Mingyang Jiang, Chenchen Chu, Lie Wu, Peng Gong & Wenhua Zhou. (2023) Combined chemotherapy based on bioactive black phosphorus for pancreatic cancer therapy. Journal of Controlled Release 354, pages 889-901.
Crossref
Crossref
Pian Yu, Shifu Luo, Jiaxin Cai, Jie Li & Cong Peng. (2022) ERAP2 as a potential biomarker for predicting gemcitabine response in patients with pancreatic cancer. Aging 14:19, pages 7941-7958.
Crossref
Crossref
Syed Saqib Ali, Ruchika Raj, Tejinder Kaur, Brenna Weadick, Debasis Nayak, Minnsung No, Jane Protos, Hannah Odom, Kajal Desai, Avinash K. Persaud, Joanne Wang & Rajgopal Govindarajan. (2022) Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective. Cancers 14:13, pages 3113.
Crossref
Crossref
A. Demet Demirag, Sefa Çelik, Sevim Akyüz & Ayşe Özel. (2021) Molecular Docking Analysis of Used Drugs for the Treatment of Cancer. Süleyman Demirel Üniversitesi Fen Bilimleri Enstitüsü Dergisi 25:3, pages 539-547.
Crossref
Crossref
Abigail Ferreira, Rui Lapa & Nuno Vale. (2021) Permeability of Gemcitabine and PBPK Modeling to Assess Oral Administration. Current Issues in Molecular Biology 43:3, pages 2189-2198.
Crossref
Crossref
E.H. Cho, J.-Y. Kim, S.-A. Im, K.H. Jung, J. Sohn, K.S. Lee, Y.S. Chae, K.H. Lee, J.H. Kim, J.-H. Jang, J.H. Ahn, M.S. Park, S.-Y. Lee & Y.H. Park. (2021) Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11). ESMO Open 6:5, pages 100236.
Crossref
Crossref
Panagiotis Sarantis, Alexandros Bokas, Adriana Papadimitropoulou, Evangelos Koustas, Stamatios Theocharis, Pavlos Papakotoulas, Dimitrios Schizas, Alexandros Papalampros, Evangelos Felekouras, Athanasios G. Papavassiliou & Michalis V. Karamouzis. (2021) Combinatorial Treatment of Tinzaparin and Chemotherapy Can Induce a Significant Antitumor Effect in Pancreatic Cancer. International Journal of Molecular Sciences 22:13, pages 7053.
Crossref
Crossref
Jimin Xu, Yu Xue, Richard Zhou, Pei‐Yong Shi, Hongmin Li & Jia Zhou. (2020) Drug repurposing approach to combating coronavirus: Potential drugs and drug targets. Medicinal Research Reviews 41:3, pages 1375-1426.
Crossref
Crossref
Xia Zhang, Rikiya Taoka, Dage Liu, Yuki Matsuoka, Yoichiro Tohi, Yoshiyuki Kakehi & Mikio Sugimoto. (2021) Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells. International Journal of Molecular Sciences 22:8, pages 4102.
Crossref
Crossref
Saffiya Habib & Moganavelli Singh. (2021) Recent Advances in Lipid-Based Nanosystems for Gemcitabine and Gemcitabine–Combination Therapy. Nanomaterials 11:3, pages 597.
Crossref
Crossref
Mercedes Garcia-Gil, Benedetta Turri, Morena Gabriele, Laura Pucci, Alessandro Agnarelli, Michele Lai, Giulia Freer, Mauro Pistello, Robert Vignali, Renata Batistoni & Silvia Marracci. (2021) Protopine/Gemcitabine Combination Induces Cytotoxic or Cytoprotective Effects in Cell Type-Specific and Dose-Dependent Manner on Human Cancer and Normal Cells. Pharmaceuticals 14:2, pages 90.
Crossref
Crossref
Manoj Amrutkar, Nils Tore Vethe, Caroline S. Verbeke, Monica Aasrum, Anette Vefferstad Finstadsveen, Petra Sántha & Ivar P. Gladhaug. (2020) Differential Gemcitabine Sensitivity in Primary Human Pancreatic Cancer Cells and Paired Stellate Cells Is Driven by Heterogenous Drug Uptake and Processing. Cancers 12:12, pages 3628.
Crossref
Crossref
Ellen J. B. Derissen & Jos H. Beijnen. (2020) Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action. Clinical Pharmacokinetics 59:12, pages 1521-1550.
Crossref
Crossref
M. Van Nuland, H. Rosing, B. Thijssen, J.A. Burgers, A.D.R. Huitema, S. Marchetti, J.H.M. Schellens & J.H. Beijnen. (2020) Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose. Clinical Pharmacology in Drug Development 9:8, pages 929-937.
Crossref
Crossref
Heng Song, Ran Cheng, Qiao-Qiao Min & Xingang Zhang. (2020) Decarboxylative and Deaminative Alkylation of Difluoroenoxysilanes via Photoredox Catalysis: A General Method for Site-Selective Synthesis of Difluoroalkylated Alkanes. Organic Letters 22:19, pages 7747-7751.
Crossref
Crossref
Brandon L. Greene, Gyunghoon KangChang Cui, Marina Bennati, Daniel G. Nocera, Catherine L. Drennan & JoAnne Stubbe. (2020) Ribonucleotide Reductases: Structure, Chemistry, and Metabolism Suggest New Therapeutic Targets. Annual Review of Biochemistry 89:1, pages 45-75.
Crossref
Crossref
Tormod K. Bjånes, Lars Petter Jordheim, Jan Schjøtt, Tina Kamceva, Emeline Cros-Perrial, Anika Langer, Gorka Ruiz de Garibay, Spiros Kotopoulis, Emmet McCormack & Bettina Riedel. (2020) Intracellular Cytidine Deaminase Regulates Gemcitabine Metabolism in Pancreatic Cancer Cell Lines. Drug Metabolism and Disposition 48:3, pages 153-158.
Crossref
Crossref
Anaïs Wambecke, Mohammad Ahmad, Bernard Lambert, Florence Joly, Laurent Poulain, Christophe Denoyelle & Matthieu Meryet-Figuiere. (2020) The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer. Gynecologic Oncology 156:3, pages 726-733.
Crossref
Crossref
Tormod Bjånes, Spiros Kotopoulis, Elisa Thodesen Murvold, Tina Kamčeva, Bjørn Tore Gjertsen, Odd Helge Gilja, Jan Schjøtt, Bettina Riedel & Emmet McCormack. (2020) Ultrasound- and Microbubble-Assisted Gemcitabine Delivery to Pancreatic Cancer Cells. Pharmaceutics 12:2, pages 141.
Crossref
Crossref
Shabir Ahmad GanaiShabir Ahmad Ganai. 2020. Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy. Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy
111
136
.
Manoj Amrutkar, Monica Aasrum, Caroline S. Verbeke & Ivar P. Gladhaug. (2019) Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells. BMC Cancer 19:1.
Crossref
Crossref
Jing Li, Dan Xu, Jian Huang, Yan-Na Wang, Xiao-Ping Ma, Zhi-Yi Lin & Ping Gong. (2019) Associations of cytosine deaminase gene polymorphisms with effectiveness of gemcitabine/cisplatin chemotherapy in patients of Xinjiang Uyghur and Han nationality with non-small cell lung cancer. The International Journal of Biological Markers 34:4, pages 389-397.
Crossref
Crossref
Ferreira, Lapa & Vale. (2019) Combination of Gemcitabine with Cell-Penetrating Peptides: A Pharmacokinetic Approach Using In Silico Tools. Biomolecules 9:11, pages 693.
Crossref
Crossref
Santos, Icyuz, Pound, William, Guo, McKinney, Niederweis, Rodgers & IV. (2019) A Humanized Yeast Phenomic Model of Deoxycytidine Kinase to Predict Genetic Buffering of Nucleoside Analog Cytotoxicity. Genes 10:10, pages 770.
Crossref
Crossref
Bulbul Ahmmed, Sylvanus Kampo, Muhammad Khan, Abdullah Faqeer, Seewooruttun Pawan kumar, Li Yulin, Ji Wei Liu & Qiu Yan. (2019) Rg3 inhibits gemcitabine‐induced lung cancer cell invasiveness through ROS‐dependent, NF‐κB‐ and HIF‐1α‐mediated downregulation of PTX3. Journal of Cellular Physiology 234:7, pages 10680-10697.
Crossref
Crossref
Xiyang Sun, Xin Xu, Yanfei Chen, Rong Guan, Tingting Cheng, Ye Wang, Rui Jin, Min Song & Taijun Hang. (2019) Danggui Buxue Decoction Sensitizes the Response of Non-Small-Cell Lung Cancer to Gemcitabine via Regulating Deoxycytidine Kinase and P-glycoprotein. Molecules 24:10, pages 2011.
Crossref
Crossref
Cancan Zhou, Weikun Qian, Jiguang Ma, Liang Cheng, Zhengdong Jiang, Bin Yan, Jie Li, Wanxing Duan, Liankang Sun, Junyu Cao, Fengfei Wang, Erxi Wu, Zheng Wu, Qingyong Ma & Xuqi Li. (2018)
Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting
SREBP
1
. Cell Proliferation 52:1.
Crossref
Crossref
L.V.K.S. Bhaskar & L. Saikrishna. 2019. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy
175
195
.
Wei Chu, Pengqian Tian, Ning Ding, Qing Cai, Jinlong Li, Xuezhi Zhuo, Zhaohui Tang, Jingxin Gou, Tian Yin, Yu Zhang, Haibing He & Xing Tang. (2018) Improving Plasma Stability and Bioavailability In Vivo of Gemcitabine Via Nanoparticles of mPEG-PLG-GEM Complexed with Calcium Phosphate. Pharmaceutical Research 35:12.
Crossref
Crossref
Xu Zhu, Sheryl Trueman, Robert M. Straubinger & William J. Jusko. (2018) Physiologically-based pharmacokinetic and pharmacodynamic models for gemcitabine and birinapant in pancreatic cancer xenografts. Journal of Pharmacokinetics and Pharmacodynamics 45:5, pages 733-746.
Crossref
Crossref
Ellen J. B. Derissen, Alwin D. R. Huitema, Hilde Rosing, Jan H. M. Schellens & Jos H. Beijnen. (2018) Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2′,2′‐difluorodeoxyuridine and their nucleotides. British Journal of Clinical Pharmacology 84:6, pages 1279-1289.
Crossref
Crossref
Xinlong Wang, Yuheng Liang, Siyang Fei, Haibing He, Yu Zhang, Tian Yin & Xing Tang. (2017) Formulation and Pharmacokinetics of HSA-core and PLGA-shell Nanoparticles for Delivering Gemcitabine. AAPS PharmSciTech 19:2, pages 812-819.
Crossref
Crossref
Daniel R. Wahl & Sriram Venneti. 2018. Imaging and Metabolism. Imaging and Metabolism
129
154
.
Beata Hryciuk, Bartosz Szymanowski, Anna Romanowska, Ewa Salt, Bartosz Wasąg, Bartłomiej Grala, Jacek Jassem & Renata Duchnowska. (2017) Severe acute toxicity following gemcitabine administration: A report of four cases with cytidine deaminase polymorphisms evaluation. Oncology Letters.
Crossref
Crossref
Manoj Amrutkar & Ivar Gladhaug. (2017) Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers 9:12, pages 157.
Crossref
Crossref
Yasuhiro Tsume, Adam Drelich, David Smith & Gordon Amidon. (2017) Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine. Molecules 22:8, pages 1322.
Crossref
Crossref
Nuno Vale, Abigail Ferreira, Iva Fernandes, Cláudia Alves, Maria João Araújo, Nuno Mateus & Paula Gomes. (2017) Gemcitabine anti-proliferative activity significantly enhanced upon conjugation with cell-penetrating peptides. Bioorganic & Medicinal Chemistry Letters 27:13, pages 2898-2901.
Crossref
Crossref
Solange Valdes, Youssef W. Naguib, Rick A. Finch, Wallace B. Baze, Christopher A. Jolly & Zhengrong Cui. (2017) Preclinical Evaluation of the Short-Term Toxicity of 4-(N)-Docosahexaenoyl 2´, 2´- Difluorodeoxycytidine (DHA-dFdC). Pharmaceutical Research 34:6, pages 1224-1232.
Crossref
Crossref
Daphne Bertholee, Jan Gerard Maring & André B. P. van Kuilenburg. (2016) Genotypes Affecting the Pharmacokinetics of Anticancer Drugs. Clinical Pharmacokinetics 56:4, pages 317-337.
Crossref
Crossref
Justine M. Grixti, Steve O'Hagan, Philip J. Day & Douglas B. Kell. (2017) Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine. Frontiers in Pharmacology 8.
Crossref
Crossref
Huixin Qi, Jia Lu, Jiajun Li, Meiyu Wang, Yunting Xu, Yedong Wang & Hongjian Zhang. (2016) Enhanced Antitumor Activity of Monophosphate Ester Prodrugs of Gemcitabine: In Vitro and In Vivo Evaluation. Journal of Pharmaceutical Sciences 105:9, pages 2966-2973.
Crossref
Crossref
Jianlin Chen, Yunmian Chu, Jin He, Lei Zheng & Xu Che. (2016) Precision medicine in the treatment of pancreatic ductal adenocarcinoma. Oncology and Translational Medicine 2:4, pages 150-155.
Crossref
Crossref
Joseph Ciccolini, Cindy Serdjebi, Godefridus J. Peters & Elisa Giovannetti. (2016) Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemotherapy and Pharmacology 78:1, pages 1-12.
Crossref
Crossref
Junjie Xiong, Kiran Altaf, Nengwen Ke, Yichao Wang, Jie Tang, Chunlu Tan, Ang Li, Hao Zhang, Du He & Xubao Liu. (2016) dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma. Medicine 95:10, pages e2936.
Crossref
Crossref
Semi B. Harrabi, Sebastian Adeberg, Marcus Winter, Thomas Haberer, Jürgen Debus & Klaus-Josef Weber. (2016)
S-phase–specific radiosensitization by gemcitabine for therapeutic carbon ion exposure
in vitro
. Journal of Radiation Research 57:2, pages 110-114.
Crossref
Crossref
Henrik Gréen, Johanna Hasmats, Ilya Kupershmidt, Daniel Edsgärd, Luigi de Petris, Rolf Lewensohn, Fiona Blackhall, Svante Vikingsson, Benjamin Besse, Andrea Lindgren, Eva Brandén, Hirsh Koyi, Curt Peterson & Joakim Lundeberg. (2016) Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities. Clinical Cancer Research 22:2, pages 366-373.
Crossref
Crossref
Tormod Bjånes, Tina Kamčeva, Torunn Eide, Bettina Riedel, Jan Schjøtt & Asbjørn Svardal. (2015) Preanalytical Stability of Gemcitabine and its Metabolite 2′, 2′-Difluoro-2′-Deoxyuridine in Whole Blood—Assessed by Liquid Chromatography Tandem Mass Spectrometry. Journal of Pharmaceutical Sciences 104:12, pages 4427-4432.
Crossref
Crossref
Yoshimasa Tokunaga, Dage Liu, Jun Nakano, Xia Zhang, Kazuhito Nii, Tetsuhiko Go, Cheng-long Huang & Hiroyasu Yokomise. (2015) Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells. European Journal of Cancer 51:16, pages 2480-2489.
Crossref
Crossref
Xu Zhu, Robert M. Straubinger & William J. Jusko. (2015) Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells. Journal of Pharmacokinetics and Pharmacodynamics 42:5, pages 477-496.
Crossref
Crossref
Min-Koo Choi, Min-Hye Kim, Han-Joo Maeng & Im-Sook Song. (2014) Contribution of CNT1 and ENT1 to ribavirin uptake in human hepatocytes. Archives of Pharmacal Research 38:5, pages 904-913.
Crossref
Crossref
Xiangxiang Ding, Wenwei Chen, Haijian Fan & Bin Zhu. (2015) Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy. Gene 559:1, pages 31-37.
Crossref
Crossref
Aldona Jakstaite. (2015) HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer. World Journal of Gastroenterology 21:46, pages 13004.
Crossref
Crossref
涛 姜. (2015) Chemotherapy for the Treatment of Adenoid Cystic Carcinoma. Hans Journal of Ophthalmology 04:03, pages 57-68.
Crossref
Crossref
Kyong-Ah Yoon, Sang Myung Woo, Eun Kyung Hong, Mee Kyung Jung, Weon Seo Park, Kieun Bae, Sung-Sik Han, Tae Hyun Kim, Young Hwan Koh, Sang-Jae Park & Woo Jin Lee. (2015) Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer. Oncology 89:6, pages 345-350.
Crossref
Crossref
CHEN XIA, FUGUI YE, XIN HU, ZHENGDONG LI, BEIQI JIANG, YUN FU, XIAOLIN CHENG, ZHIMING SHAO & ZHIGANG ZHUANG. (2014) Liver kinase B1 enhances chemoresistance to gemcitabine in breast cancer MDA-MB-231 cells. Oncology Letters 8:5, pages 2086-2092.
Crossref
Crossref
Maria L. Alvarellos, Jatinder Lamba, Katrin Sangkuhl, Caroline F. Thorn, Liewei Wang, Daniel J. Klein, Russ B. Altman & Teri E. Klein. (2014) PharmGKB summary. Pharmacogenetics and Genomics 24:11, pages 564-574.
Crossref
Crossref
Lucas de Sousa Cavalcante & Gisele Monteiro. (2014) Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. European Journal of Pharmacology 741, pages 8-16.
Crossref
Crossref
Suparna Qanungo, Joachim D. Uys, Yefim Manevich, Anne M. Distler, Brooke Shaner, Elizabeth G. Hill, John J. Mieyal, John J. Lemasters, Danyelle M. Townsend & Anna-Liisa Nieminen. (2014) N-acetyl-l-cysteine sensitizes pancreatic cancers to gemcitabine by targeting the NFκB pathway. Biomedicine & Pharmacotherapy 68:7, pages 855-864.
Crossref
Crossref
Wei-Hua Hao, Li-Chieh Yang, Jong-Jing Wang, Chang-Shan Hsu, Li-Chien Chang & Kuang-Yang Hsu. (2014) Facile method for determination of deoxycytidine kinase activity in biological milieus. Journal of Food and Drug Analysis 22:2, pages 236-241.
Crossref
Crossref
Daniela Micozzi, Francesco Martino Carpi, Stefania Pucciarelli, Valeria Polzonetti, Paolo Polidori, Santiago Vilar, Brian Williams, Stefano Costanzi & Silvia Vincenzetti. (2014) Human cytidine deaminase: A biochemical characterization of its naturally occurring variants. International Journal of Biological Macromolecules 63, pages 64-74.
Crossref
Crossref
A Khatri, B W Williams, J Fisher, R C Brundage, V J Gurvich, L G Lis, K M Skubitz, A Z Dudek, E W Greeno, R A Kratzke, J K Lamba & M N Kirstein. (2013) SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours. British Journal of Cancer 110:2, pages 304-312.
Crossref
Crossref
Ingrid Jakobsen Falk, Anna Fyrberg, Esbjörn Paul, Hareth Nahi, Monica Hermanson, Richard Rosenquist, Martin Höglund, Lars Palmqvist, Dick Stockelberg, Yuan Wei, Henrik Gréen & Kourosh Lotfi. (2013) Decreased survival in normal karyotype AML with single‐nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5′‐nucleotidase. American Journal of Hematology 88:12, pages 1001-1006.
Crossref
Crossref
Christina H. Wei, Tristan R. Gorgan, David A. Elashoff, O. Joe Hines, James J. Farrell & Timothy R. Donahue. (2013) A Meta-Analysis of Gemcitabine Biomarkers in Patients With Pancreaticobiliary Cancers. Pancreas 42:8, pages 1303-1310.
Crossref
Crossref
Sau Wai Hung, Hardik Mody, Sean Marrache, Yangzom D. Bhutia, Franklin Davis, Jong Hyun Cho, Jason Zastre, Shanta Dhar, Chung K. Chu & Rajgopal Govindarajan. (2013) Pharmacological Reversal of Histone Methylation Presensitizes Pancreatic Cancer Cells to Nucleoside Drugs: In Vitro Optimization and Novel Nanoparticle Delivery Studies. PLoS ONE 8:8, pages e71196.
Crossref
Crossref
Sumit Arora, Arun Bhardwaj, Seema Singh, Sanjeev K. Srivastava, Steven McClellan, Chaitanya S. Nirodi, Gary A. Piazza, William E. Grizzle, Laurie B. Owen & Ajay P. Singh. (2013) An Undesired Effect of Chemotherapy. Journal of Biological Chemistry 288:29, pages 21197-21207.
Crossref
Crossref
Sandhya N. Iyer, Arunkanth Ankala, Rekha S. Singhal & Madhuri R. Hegde. (2013) Determination of common genetic variants in cytidine deaminase (CDA) gene in Indian ethnic population. Gene 524:1, pages 35-39.
Crossref
Crossref
Saurabh Singh, Deepak Chitkara, Virender Kumar, Stephen W. Behrman & Ram I. Mahato. (2013) miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Letters 334:2, pages 211-220.
Crossref
Crossref
Meng Zhang, Jing Wang, RuYong Yao & LiMing Wang. (2013) Small Interfering RNA (siRNA)-Mediated Silencing of the M2 Subunit of Ribonucleotide Reductase. International Journal of Gynecological Cancer 23:4, pages 659-666.
Crossref
Crossref
Míriam Molina‐Arcas & Marçal Pastor‐Anglada. 2013. Pharmacogenomics of Human Drug Transporters. Pharmacogenomics of Human Drug Transporters
243
270
.
Rachel A. Kudgus, Annamaria Szabolcs, Jameel Ahmad Khan, Chad A. Walden, Joel M. Reid, J. David Robertson, Resham Bhattacharya & Priyabrata Mukherjee. (2013) Inhibiting the Growth of Pancreatic Adenocarcinoma In Vitro and In Vivo through Targeted Treatment with Designer Gold Nanotherapeutics. PLoS ONE 8:3, pages e57522.
Crossref
Crossref
Yangzom Doma Bhutia, Sau Wai Hung, Madeline Krentz, Dimal Patel, Dylan Lovin, Radhika Manoharan, J. Michael Thomson & Rajgopal Govindarajan. (2013) Differential Processing of let-7a Precursors Influences RRM2 Expression and Chemosensitivity in Pancreatic Cancer: Role of LIN-28 and SET Oncoprotein. PLoS ONE 8:1, pages e53436.
Crossref
Crossref
Christopher B. Steer & Gabriel W. H. Mak. 2013. Management of Gynecological Cancers in Older Women. Management of Gynecological Cancers in Older Women
83
98
.
Daniel Braas, Ethan Ahler, Brenna Tam, David Nathanson, Mirielle Riedinger, Matthias R. Benz, Kathleen B. Smith, Fritz C. Eilber, Owen N. Witte, William D. Tap, Hong Wu & Heather R. Christofk. (2012) Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment. Cancer Discovery 2:12, pages 1109-1117.
Crossref
Crossref
Alexander V. LyubimovRonald E. White. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
40
.
Chin-Sheng Hung, Shen-Fu Lin, Hui-Hsiung Liu, Li-Jen Kuo, Li-Tzu Li, Hou-Yu Su, Phui-Ly Liew, Feng-Yen Lin, Po-Li Wei, Der-Zen Liu & Yu-Jia Chang. (2012) Survivin-mediated Therapeutic Efficacy of Gemcitabine through Glucose-regulated Protein 78 in Hepatocellular Carcinoma. Annals of Surgical Oncology 19:8, pages 2744-2752.
Crossref
Crossref
Jialin Xu, Yuhong Zhou, Jing Zhang, Yuancheng Chen, Rongyuan Zhuang, Tianshu Liu & Weimin Cai. (2012) High incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutation. Clinica Chimica Acta 413:15-16, pages 1284-1287.
Crossref
Crossref
Wei-Yu Liao, Jin-Yuan Shih, Gee-Chen Chang, Yu-Kai Cheng, James Chih-Hsin Yang, Yuh-Min Chen & Chong-Jen Yu. (2012) Genetic Polymorphism of XRCC1 Arg399Gln Is Associated With Survival in Non?Small-Cell Lung Cancer Patients Treated With Gemcitabine/Platinum. Journal of Thoracic Oncology 7:6, pages 973-981.
Crossref
Crossref
Min-Koo Choi. (2012) Variability of gemcitabine accumulation and its relationship to expression of nucleoside transporters in peripheral blood mononuclear cells. Archives of Pharmacal Research 35:5, pages 921-927.
Crossref
Crossref
Matthias Schwab, Elke Schaeffeler & Hiltrud Brauch. 2012. Metabolism of Drugs and Other Xenobiotics. Metabolism of Drugs and Other Xenobiotics
365
378
.
Yuriko Saiki, Yuki Yoshino, Hiroko Fujimura, Tatsuya Manabe, Yuki Kudo, Miki Shimada, Nariyasu Mano, Tomohiro Nakano, Yoonha Lee, Shinjiro Shimizu, Shinya Oba, Sho Fujiwara, Hideyuki Shimizu, Na Chen, Zhaleh Kashkouli Nezhad, Guo Jin, Shinichi Fukushige, Makoto Sunamura, Masaharu Ishida, Fuyuhiko Motoi, Shinichi Egawa, Michiaki Unno & Akira Horii. (2012) DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells. Biochemical and Biophysical Research Communications 421:1, pages 98-104.
Crossref
Crossref
Myrna Candelaria, Erick de la Cruz-Hernandez, Lucia Taja-Chayeb, Enrique Perez-Cardenas, Catalina Trejo-Becerril, Aurora Gonzalez-Fierro, Alma Chavez-Blanco, Ernesto Soto-Reyes, Guadalupe Dominguez, Jaenai E. Trujillo, Jose Diaz-Chavez & Alfonso Duenas-Gonzalez. (2012) DNA Methylation-Independent Reversion of Gemcitabine Resistance by Hydralazine in Cervical Cancer Cells. PLoS ONE 7:3, pages e29181.
Crossref
Crossref
Liang Li, Daniel J. Schaid, Brooke L. Fridley, Krishna R. Kalari, Gregory D. Jenkins, Ryan P. Abo, Anthony Batzler, Irene Moon, Linda Pelleymounter, Bruce W. Eckloff, Eric D. Wieben, Zhifu Sun, Ping Yang & Liewei Wang. (2012) Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer. Pharmacogenetics and Genomics 22:2, pages 105-116.
Crossref
Crossref
Hironori Motoshige, Kyohei Oyama, Kiyoshi Takahashi & Koichi Sakurai. (2012) Involvement of Phosphatidylinositol 3-Kinase/Akt Pathway in Gemcitabine-Induced Apoptosis-Like Cell Death in Insulinoma Cell Line INS-1. Biological and Pharmaceutical Bulletin 35:11, pages 1932-1940.
Crossref
Crossref
Zaklina Kovacevic, Sherin Chikhani, David B. Lovejoy & Des R. Richardson. (2011) Novel Thiosemicarbazone Iron Chelators Induce Up-Regulation and Phosphorylation of the Metastasis Suppressor N-myc Down-Stream Regulated Gene 1: A New Strategy for the Treatment of Pancreatic Cancer. Molecular Pharmacology 80:4, pages 598-609.
Crossref
Crossref
Jeong-Seon Ryu, Eun-Soon Shin, Hae-Seong Nam, Hyeon-Gyu Yi, Jae-Hwa Cho, Chul-Soo Kim, Hyun-Jung Kim & Jong-Eun Lee. (2011) Differential Effect of Polymorphisms of CMPK1 and RRM1 on Survival in Advanced Non-small Cell Lung Cancer Patients Treated with Gemcitabine or Taxane/Cisplatinum. Journal of Thoracic Oncology 6:8, pages 1320-1329.
Crossref
Crossref
Yunjian Xu, Anna Karlsson & Magnus Johansson. (2011) Identification of genes associated to 2′,2′-difluorodeoxycytidine resistance in HeLa cells with a lentiviral short-hairpin RNA library. Biochemical Pharmacology 82:3, pages 210-215.
Crossref
Crossref
Joseph Ciccolini, Cédric Mercier, Laetitia Dahan & Nicolas André. (2011) Integrating pharmacogenetics into gemcitabine dosing—time for a change?. Nature Reviews Clinical Oncology 8:7, pages 439-444.
Crossref
Crossref
P. Specenier, G. Guetens, J. Dyck, G. De Boeck, J. Weyler, D. Van den Weyngaert, K. Aelbrecht & J. B. Vermorken. (2010) Difluorodeoxyuridine plasma concentrations after low-dose gemcitabine during chemoradiation in head and neck cancer patients. Cancer Chemotherapy and Pharmacology 68:1, pages 185-191.
Crossref
Crossref
Fei Yan, Xiang Li, Qiaofeng Jin, Chunxiang Jiang, Zidong Zhang, Tao Ling, Bensheng Qiu & Hairong Zheng. (2011) Therapeutic Ultrasonic Microbubbles Carrying Paclitaxel and LyP-1 Peptide: Preparation, Characterization and Application to Ultrasound-Assisted Chemotherapy in Breast Cancer Cells. Ultrasound in Medicine & Biology 37:5, pages 768-779.
Crossref
Crossref
Yangzom D. Bhutia, Sau Wai Hung, Bhavi Patel, Dylan Lovin & Rajgopal Govindarajan. (2011) CNT1 Expression Influences Proliferation and Chemosensitivity in Drug-Resistant Pancreatic Cancer Cells. Cancer Research 71:5, pages 1825-1835.
Crossref
Crossref
Milena Gusella, Felice Pasini, Caterina Bolzonella, Silvia Meneghetti, Carmen Barile, Antonio Bononi, Silvia Toso, Daniela Menon, Giorgio Crepaldi, Yasmina Modena, Laura Stievano & Roberto Padrini. (2011) Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours. British Journal of Clinical Pharmacology 71:3, pages 437-444.
Crossref
Crossref
Jorge A. Garcia, Thomas E. Hutson, Dale Shepard, Paul Elson & Robert Dreicer. (2010) Gemcitabine and docetaxel in metastatic, castrate‐resistant prostate cancer. Cancer 117:4, pages 752-757.
Crossref
Crossref
Christine L. Clouser, Colleen M. Holtz, Mary Mullett, Duane L. Crankshaw, Jacquie E. Briggs, Jay Chauhan, Ilze Matise VanHoutan, Steven E. Patterson & Louis M. Mansky. (2011) Analysis of the Ex Vivo and In Vivo Antiretroviral Activity of Gemcitabine. PLoS ONE 6:1, pages e15840.
Crossref
Crossref
Ioannis A Voutsadakis. (2011) Molecular predictors of gemcitabine response in pancreatic cancer. World Journal of Gastrointestinal Oncology 3:11, pages 153.
Crossref
Crossref
Teppei Morikawa, Daichi Maeda, Haruki Kume, Yukio Homma & Masashi Fukayama. (2010) Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer. Histopathology 57:6, pages 885-892.
Crossref
Crossref
Seung Jin Lee, Seog Young Kim, Jin Hwa Chung, Seung Jun Oh, Jin Sook Ryu, Yong Sang Hong, Tae Won Kim & Dae Hyuk Moon. (2010) Induction of thymidine kinase 1 after 5-fluorouracil as a mechanism for 3′-deoxy-3′-[18F]fluorothymidine flare. Biochemical Pharmacology 80:10, pages 1528-1536.
Crossref
Crossref
Elisa Giovannetti, Carmelo Tibaldi, Alfredo Falcone, Romano Danesi & Godefridus J. Peters. (2010) Impact of Cytidine Deaminase Polymorphisms on Toxicity After Gemcitabine: The Question Is Still Ongoing. Journal of Clinical Oncology 28:14, pages e221-e222.
Crossref
Crossref